SEMA6A as a Radioligand Therapy Target
SEMA6A, semaphorin 6A, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, SEMA6A staining is highest in ovarian cancer (100% of samples positive), liver cancer (100% of samples positive) and lung cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is SEMA6A a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in ovarian cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
SEMA6A expression in cancer
Protein expression of SEMA6A across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Ovarian Cancer | 1.00 | High | 100% |
| Liver Cancer | 0.97 | High | 100% |
| Lung Cancer | 0.97 | High | 100% |
| Endometrial Cancer | 0.97 | High | 100% |
| Colorectal Cancer | 0.97 | High | 100% |
| Gastric Cancer | 0.96 | High | 100% |
| Pancreatic Cancer | 0.94 | High | 100% |
| Prostate Cancer | 0.93 | High | 100% |
| Melanoma | 0.92 | High | 100% |
| Bladder Cancer | 0.91 | High | 100% |
| Breast Cancer | 0.88 | High | 100% |
| Skin Cancer | 0.85 | High | 100% |
| Thyroid Cancer | 0.83 | High | 100% |
| Neuroendocrine Tumors | 0.83 | High | 100% |
| Cervical Cancer | 0.82 | High | 100% |
| Testicular Cancer | 0.79 | High | 100% |
| Head and Neck Cancer | 0.75 | High | 100% |
| Lymphoma | 0.67 | High | 100% |
| Kidney Cancer | 0.60 | High | 100% |
| Glioma | 0.55 | High | 82% |
Is SEMA6A internalized?
Nuclens has not yet extracted internalization evidence for SEMA6A. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
SEMA6A clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for SEMA6A yet. Search ClinicalTrials.gov for SEMA6A trials.
SEMA6A normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SEMA6A in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
SEMA6A gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: 0.05 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related ovarian cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · Mesothelin (MSLN) · EPCAM · STEAP2 · FAP · ITGAV · EGFR
See all radioligand therapy targets in ovarian cancer.
See how SEMA6A ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.